Clinical Trial: Ketotifen/Naphazoline Ophthalmic Solution in the Conjunctival Allergen Challenge Model of Acute Allergic Conjunctivitis

This clinical trial will determine if ketotifen/naphazoline is an effective treatment for acute allergic conjunctivitis.

Click here to access this third party resource:

Ketotifen/Naphazoline Ophthalmic Solution in the Conjunctival Allergen Challenge Model of Acute Allergic Conjunctivitis

Study Type: Interventional

Age/Gender Requirements: 6 years+ (male/female)

Sponsor: Bausch & Lomb, Inc.

Purpose: To determine the safety and efficacy of ketotifen/naphazoline ophthalmic solution “compared to vehicle and its individual components in alleviating the signs and symptoms of conjunctival allergen challenge (CAC)-induced allergic conjunctivitis.”

Related Videos
Experts on inflammatory bowel disease.
Experts on inflammatory bowel disease.
Victor Kim, MD: Addressing Comorbidities and Advancing COPD Care
Victor-Kim-MD
Related Content
© 2023 MJH Life Sciences

All rights reserved.